Leading Companies

Aurealis Therapeutics AG

Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The genetically modified lactic acid bacteria based therapy is designed to improve the quality of life for patients who requires tissue generation for example with diabetic foot ulcer. This is remarkable advancement for people who generally have only had access to medicines that treat symptoms versus promote tissue regeneration itself.

Aurealis Therapeutics AG

4057 Basel

Life Science
Bio Technology (Biotech)
Chemical & Pharmaceutical Technology
Country of Origin
En savoir plus sur le sujet

Partenaire Premium

Partenaires stratégiques

Partenaire institutionnel

Programme officiel